[25] L. Verrilli and S. L. Berga, “What Every Gynecologist Should Know About Perimenopause,” Clin. Obstet. Gynecol., vol. 63, no. 4, pp. 720–734, Dec. 2020, doi: 10.1097/GRF.0000000000000578.
[26] P. Paramsothy et al., “Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation.,” Menopause, vol. 24, no. 2, pp. 142–149, Feb. 2017, doi: 10.1097/GME.0000000000000736.
[27] E. Armeni et al., “Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS).,” Maturitas, vol. 89, pp. 63–72, Jul. 2016, doi: 10.1016/j.maturitas.2016.04.013.
[28] W. H. Natcher, “NIH State-of-the-Science Conference on Management of Menopause-Related Symptoms Sponsored by : National Institutes of Health,” Heal. (San Fr., vol. 3, p. 118(suppl 2):1–172, 2005.
[29] E V Shlyakhto, G T Sukhikh, V N Serov, I I Dedov, G P Arutyunov, I A Suchkov, Ya A Orlova, E N Andreeva, S V Yureneva, I S Yavelov, M I Yarmolinskaya, S V Villevalde, O R Grigoryan, E N Dudinskaya, E A Ilyukhin, N A Koziolova, I V Sergienko, A A Smetnik, N I Tapilskaya “Russian eligibility criteria prescribing menopausal hormonal hormones therapy for patients with cardiovascular and metabolic diseases. Consensus document of the Russian Cardiological Society, Russian Society of Obstetricians and Gynecologists, Russian Ass,” Probl. Endocrinol., vol. 69, no. 5, pp. 115–136, Nov. 2023, doi: 10.14341/probl13394.
[30] A. L. Hirschberg, “Hyperandrogenism and Cardiometabolic Risk in Pre- and Postmenopausal Women-What Is the Evidence?,” J. Clin. Endocrinol. Metab., vol. 109, no. 5, pp. 1202–1213, Apr. 2024, doi: 10.1210/clinem/dgad590.
[31] C. A. Stuenkel, “Reproductive milestones across the lifespan and cardiovascular disease risk in women,” Climacteric, vol. 27, no. 1, pp. 5–15, Jan. 2024, doi: 10.1080/13697137.2023.2259793.
[32] P. Monteleone, G. Mascagni, A. Giannini, A. R. Genazzani, and T. Simoncini, “Symptoms of menopause — global prevalence, physiology and implications,” Nat. Rev. Endocrinol., vol. 14, no. 4, pp. 199–215, 2018, doi: 10.1038/nrendo.2017.180.
[33] P. M. Maki et al., “Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations,” J. Women’s Heal., vol. 28, no. 2, pp. 117–134, 2019, doi: 10.1089/jwh.2018.27099.mensocrec.
[34] E. S. Mitchell and N. F. Woods, “Cognitive symptoms during the menopausal transition and early postmenopause,” Climacteric, vol. 14, no. 2, pp. 252–261, Apr. 2011, doi: 10.3109/13697137.2010.516848.
[35] S. R. El Khoudary et al., “Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.,” Circulation, vol. 142, no. 25, pp. e506–e532, Dec. 2020, doi: 10.1161/CIR.0000000000000912.
[36] H. M. Kravitz and H. Joffe, “Sleep During the Perimenopause: A SWAN Story,” Obstetrics and Gynecology Clinics of North America, vol. 38, no. 3. Elsevier, pp. 567–586, Sep. 2011. doi: 10.1016/j.ogc.2011.06.002.
[37] S. M. Mallhi TH, Khan YH, Khan AH, Mahmood Q, Khalid SH, “Managing Hot Flushes in Menopausal Women: A Review,” J Coll Physicians Surg Pak., vol. Jun;28(6), pp. 460–465, 2018, doi: doi: 10.29271/jcpsp.2018.06.460.
[38] M. R. Islam, P. Gartoulla, R. J. Bell, P. Fradkin, and S. R. Davis, “Prevalence of menopausal symptoms in Asian midlife women: a systematic review,” Climacteric, vol. 18, no. 2, pp. 157–176, Mar. 2015, doi: 10.3109/13697137.2014.937689.
[39] S. Chaikittisilpa, K. Soimongkol, and U. Jaisamrarn, “Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women,” Climacteric, vol. 22, no. 5, pp. 460–465, Sep. 2019, doi: 10.1080/13697137.2019.1577378.
[40] G. Sarri, H. Pedder, S. Dias, Y. Guo, and M. A. Lumsden, “Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause,” BJOG An Int. J. Obstet. Gynaecol., vol. 124, no. 10, pp. 1514–1523, Sep. 2017, doi: https://doi.org/10.1111/1471-0528.14619.
[41] ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI, Panay N, Anderson RA, et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024;27(6):510-520. doi:10.1080/13697137.2024.2423213.
[42] D. Harlow, P. Maki, R. W. Rebar, and E. Director, “President, International Menopause Society (South Africa),” Climacteric, vol. 15, no. 2, pp. 105–114, 2012, doi: 10.3109/13697137.2011.650656.
[43] “Приказ Министерства здравоохранения Российской Федерации от 20.10.2020 № 1130н ‘Об утверждении Порядка оказания медицинской помощи по профилю ’акушерство и гинекология"”.
[44] “Доброкачественная дисплазия молочной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации.,” p. 77, 2020.
[45] M. A. Lumsden, “The NICE Guideline – Menopause: diagnosis and management,” Climacteric, vol. 19, no. 5, pp. 426–429, Sep. 2016, doi: 10.1080/13697137.2016.1222483.
[46] Юренева С.В., Ермакова Е.И., Павлович С.В., Корнеева И.Е., Смольникова В.Ю., Мишиева Н.Г. Ведение женщин с менопаузальными расстройствами. Учебное пособие. М.: ГЭОТАР-Медиа. 2016;23-26.
[47] С. В. Ермакова, Е.И, Юренева, “Менопауза и климактерическое состояние у женщины,” Акушерство и гинекология., vol. 7, pp. 17–21, 2018.
[48] S. V. Yureneva, V. I. Komedina, and S. Y. Kuznetsov, “Weight gain in perimenopausal women: methods for assessing the body composition and maintenance tactics,” Akush. Ginekol. (Sofiia)., vol. 2_2020, pp. 56–61, Mar. 2020, doi: 10.18565/aig.2020.2.56-61.